AstraZeneca Reports Positive Results From Phase III Trial With Datopotamab Deruxtecan
22/9 08:26
(RTTNews) - AstraZeneca PLC (AZN.L, AZN) said high-level results from the TROPION-Breast01 Phase III trial with datopotamab deruxtecan showed a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival compared to invest...